计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| A129732-10mg |
10mg |
现货 ![]() |
| |
| A129732-50mg |
50mg |
现货 ![]() |
| |
| A129732-250mg |
250mg |
现货 ![]() |
| |
| A129732-1g |
1g |
期货 ![]() |
| |
| A129732-5g |
5g |
期货 ![]() |
|
| 别名 | 阿西替尼 | N-甲基-2-((3-((1E)-2-(吡啶-2-基)乙烯)-1H-吲唑-6-基)硫)苯甲酰胺 | AG-013736 | N-甲基-2-[[3-[(1E)-2-(吡啶-2-基)乙烯基]-1H-吲唑-6-基]硫基]苯甲酰胺 | (E)-N-甲基-2-[[3-[2-(吡啶-2-基)乙烯基]-1H-吲唑-6-基]硫代]苯甲酰胺 |
|---|---|
| 英文别名 | AG13736 | AG-13736 | Benzamide, N-methyl-2-((3-((1E)-2-(2-pyridinyl)ethenyl)-1H-indazo)-6-yl)thio)- | NCGC00241108-04 | N-methyl-2-({3-[(1E)-2-(pyridin-2-yl)ethenyl]-1H-indazol-6-yl}sulfanyl)benzamide | SR-01000941566 | SR-01000941566-1 | BRD-K29905972-00 |
| 规格或纯度 | Moligand™, ≥99% |
| 英文名称 | Axitinib |
| 生化机理 | VEGFR-2,-3和-1的有效抑制剂(IC50值分别为0.2、0.1-0.3和1.2 nM)。对一组约100种蛋白激酶的活性最低。抑制血管生成和血管通透性。也是一种高亲和力的BCR-ABL1(T315I)抑制剂(自磷酸化ABL1(T315I)的Ki = 149 pM)。阻止表达BCR-ABL1(T315I)的Ba / F3细胞的增殖。口服。 |
| 应用 | An inhibitor of Flt and Flk (VEGFR) with antitumor properties |
| 储存温度 | 避光,-20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 血管内皮生长因子受体抑制剂 |
| 产品介绍 |
应用: 阿昔替尼已被用作血管内皮生长因子 (VEGF) 受体酪氨酸激酶抑制剂 (TKI) ,以研究其对肾癌细胞体外增殖的影响。 此外,在调理水 (CW) 中维持的脱氯胚胎中,它还用于抑制肠系膜上动脉 (AMA) 血管生成。
Axitinib is a non-selective receptor kinase inhibitor of Flt and Flk proteins. This compound also inhibits Flt-1(VEGFR-1), Flk-1(VEGFR-2), Flt-4(VEGFR-3), PDGFR-β and c-Kit(c-KIT) with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM, respectively. Axitinib is studied as an antitumor agent of various cell lines. Axitinib is an inhibitor of PDGFR-β.An inhibitor of Flt and Flk (VEGFR) with antitumor properties
Application:
Axitinib has been used as a vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor (TKI) to study its effect on renal cancer cell proliferation in vitro. It has also been used to inhibit anterior mesenteric artery (AMA) angiogenesis in dechlorinated embryos maintained in conditioned water (CW). |
| 纯度 | ≥99% |
| ALogP | 4.2 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 488195799 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide |
| INCHI | 1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+ |
| InChi Key | RITAVMQDGBJQJZ-FMIVXFBMSA-N |
| Smiles | CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)C=CC4=CC=CC=N4 |
| Isomeric SMILES | CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)/C=C/C4=CC=CC=N4 |
| 分子量 | 386.47 |
| Reaxy-Rn | 14436737 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=14436737&ln= |
| 溶解性 | 溶于DMSO, 最高浓度 (mg/mL): 9.66, 最高浓度(mM): 25 |
|---|---|
| 敏感性 | 对光线、湿度、热、空气敏感 |
| 分子量 | 386.500 g/mol |
| XLogP3 | 4.200 |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 4 |
| 可旋转键计数Rotatable Bond Count | 5 |
| 精确质量Exact Mass | 386.12 Da |
| 单同位素质量Monoisotopic Mass | 386.12 Da |
| 拓扑极表面积Topological Polar Surface Area | 96.000 Ų |
| 重原子数Heavy Atom Count | 28 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 557.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 1 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 1 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 象形图 | GHS07, GHS08, GHS09 |
|---|---|
| 信号词 | 警告 |
| 危险声明 |
H302: 吞食有害 H341: 怀疑引起遗传缺陷 H361: 怀疑破坏生育力或未出生的孩子 H373: 通过长时间或反复暴露对器官造成损害 H400: 对水生生物有剧毒 |
| 预防措施声明 |
P260: 不要吸入灰尘/烟雾/气体/雾/蒸汽/喷雾。 P264: 处理后要彻底洗手。 P270: 使用本产品时,请勿进食、饮水或吸烟。 P273: 避免释放到环境中。 P280: 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。 P281: 根据需要使用个人防护设备。 P330: 漱口 P391: 收集溢出物 P405: 密闭存放 P501: 将内容物/容器处理到。。。 P203: 使用前,获取、阅读并遵守所有安全说明。 P301+P317: 如果被吞咽:请寻求医疗帮助。 P318: 如果暴露或担心,请就医。 P319: 如果你感到不适,请寻求医疗帮助。 |
| WGK Germany | 3 |
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | A129732 | |
| 分析证书 | A129732 | |
| 分析证书 | A129732 | |
| 分析证书 | A129732 | |
| 分析证书 | A129732 | |
| 分析证书 | A129732 | |
| 分析证书 | A129732 | |
| 分析证书 | A129732 | |
| 分析证书 | A129732 | |
| 分析证书 | A129732 | |
| 分析证书 | A129732 | |
| 分析证书 | A129732 | |
| 分析证书 | A129732 |
¥407.92
| 1. Yunsheng Ran, Chujiao Hu, Junzhao Wan, Qian Kang, Ruixian Zhou, Ping Liu, Dan Ma, Jianta Wang, Lei Tang. (2023) Integrated investigation and experimental validation of PPARG as an oncogenic driver: implications for prognostic assessment and therapeutic targeting in hepatocellular carcinoma. Frontiers in Pharmacology, 14 (1298341). [PMID:38044948] [10.3389/fphar.2023.1298341] |
| 2. Fangjun Chen, Wenda Chen, Zhenxin Wang, Yingfei Peng, Beili Wang, Baishen Pan, Wei Guo. (2023) Development and clinical application of a liquid chromatography-tandem mass spectrometry-based assay to quantify eight tyrosine kinase inhibitors in human plasma. Journal of Mass Spectrometry and Advances in the Clinical Lab, 29 (2). [PMID:37234251] [10.1016/j.jmsacl.2023.05.001] |
| 3. Zhao-Yang Wang, Hai-Long Wu, Yue-Yue Chang, Tong Wang, Wei Chen, Gao-Yan Tong, Ru-Qin Yu. (2021) Simultaneous determination of nine tyrosine kinase inhibitors in three complex biological matrices by using high-performance liquid chromatography–diode array detection combined with a second-order calibration method. JOURNAL OF SEPARATION SCIENCE, 44 (21): (3914-3923). [PMID:34463059] [10.1002/jssc.202100293] |
| 4. Yue-Yue Chang, Hai-Long Wu, Huan Fang, Tong Wang, Yang-Zi Ouyang, Xiao-Dong Sun, Gao-Yan Tong, Yu-Jie Ding, Ru-Qin Yu. (2021) Comparison of three chemometric methods for processing HPLC-DAD data with time shifts: Simultaneous determination of ten molecular targeted anti-tumor drugs in different biological samples. TALANTA, 224 (121798). [PMID:33379025] [10.1016/j.talanta.2020.121798] |
| 5. Weizhen Chen, Kui Xu, Bailong Tao, Liangliang Dai, Yonglin Yu, Caiyun Mu, Xinkun Shen, Yan Hu, Ye He, Kaiyong Cai. (2018) Multilayered coating of titanium implants promotes coupled osteogenesis and angiogenesis in vitro and in vivo. Acta Biomaterialia, 74 (489). [PMID:29702291] [10.1016/j.actbio.2018.04.043] |